William on for Mayank Mumtani's questions to Cytokinetics Inc (CYTK) leadership • Q2 2025
Question
An analyst on for Mayank Mumtani at B. Riley Securities asked how data from MAPLE and SEQUOIA support the ACACIA (nHCM) trial and how the oHCM REMS might read through to nHCM.
Answer
Fady Malik, EVP of R&D, explained that data from both trials showing aficamtan's improvement in diastolic function is highly relevant and supportive for ACACIA's potential success. Stuart Kupfer, SVP & CMO, added that the favorable safety profile is also expected to carry through. They stated it was too early to speculate on a REMS for nHCM.